Dalfampridine improves slowed processing speed in MS: Picking up the pace

Cognitive decline is recognized as a prevalent and debilitating symptom of multiple sclerosis (MS),1 with cognitive changes often occurring early in the disease course.2 Even relatively subtle cognitive decline can have substantial real-life consequences, including negative effects on employment3 and quality of life, both for people with MS and their caregivers.4 Heightened awareness of disease-related cognitive decline has motivated cognitive screenings as a key component of comprehensive care at clinical MS centers; however, increased awareness and clinical attention has also highlighted the lack of effective symptomatic treatments for cognitive deficits.5,6 Obstacles encumbering validation of effective treatments have been discussed,1 including a lack of methodologic rigor in clinical trials aiming to improve cognition.5,6

Source link

Related posts

Peripheral synucleinopathy in a DJ1 patient with Parkinson disease, cataracts, and hearing loss


Repetitive TMS for Parkinson Disease Depression Non-Superior to SSRI Therapy


Therapeutic effects of forced exercise cycling in individuals with Parkinson's disease


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy